Department of Pharmacology and Center for Innovation in Chemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
J Ethnopharmacol. 2011 Apr 12;134(3):789-95. doi: 10.1016/j.jep.2011.01.037. Epub 2011 Feb 1.
Since the use of Nelumbo nucifera stamens in herbal medicines as well as in cosmetic products are highly prevalent in Thailand and increasing worldwide, acute and subchronic toxicity studies to confirm the safe use of Nelumbo nucifera stamens are warranted.
Acute and subchronic oral toxicity studies of Nelumbo nucifera stamens extract in rats were performed in the present study in order to evaluate its safety.
In acute toxicity study, Nelumbo nucifera stamens extract was administered by oral gavage to Sprague-Dawley rats (5 males and 5 females) at a dose of 5000 mg/kg. In subchronic toxicity study, the extract at doses of 50, 100, and 200mg/kg/day were given orally to groups of rats (6 rats/dose/sex) for 90 consecutive days.
The extract at a dose of 5000 mg/kg produced no treatment-related signs of toxicity or mortality in any of the animals tested during 14 days of the study. In the repeated dose 90-day oral toxicity study, there was no significant difference in body weight between the control and all treatment groups with the exception of the body weight of the female group treated with 200mg/kg/day of the extract which was statistically significantly less than that of its control counterpart on day 90 but the percent weight changes of both groups were almost similar. Some statistically significant differences in hematological and biochemical parameters as well as in some internal organ weights of both male and female rats treated with the extract at the highest dose were observed. However, no abnormality of internal organs was observed in both gross and histopathological examinations.
These results suggest that the oral lethal dose of Nelumbo nucifera stamens extract for male and female rats is in excess of 5000 mg/kg and the no-observed-adverse-effect level (NOAEL) of the extract for both male and female rats is considered to be 200mg/kg/day.
由于在泰国乃至全球范围内,荷花雄蕊被广泛应用于草药和化妆品中,因此有必要进行急性和亚慢性毒性研究,以确认荷花雄蕊的使用安全性。
本研究旨在进行荷花雄蕊提取物的急性和亚慢性口服毒性研究,以评估其安全性。
在急性毒性研究中,荷花雄蕊提取物以 5000mg/kg 的剂量经口灌胃给予 Sprague-Dawley 大鼠(雄性和雌性各 5 只)。在亚慢性毒性研究中,将提取物以 50、100 和 200mg/kg/天的剂量分别给予大鼠(每组 6 只/剂量/性别),连续 90 天。
在为期 14 天的研究中,剂量为 5000mg/kg 的提取物未在任何受试动物中产生与治疗相关的毒性体征或死亡。在重复剂量 90 天口服毒性研究中,除了每日 200mg/kg 剂量组的雌性大鼠体重与对照组相比在第 90 天有统计学显著差异外,对照组和所有治疗组之间的体重无显著差异,但两组的体重变化百分比几乎相似。在接受最高剂量提取物的雄性和雌性大鼠的血液学和生化学参数以及一些内脏器官重量方面观察到一些具有统计学显著差异。然而,在大体和组织病理学检查中均未观察到内脏器官异常。
这些结果表明,荷花雄蕊提取物对雄性和雌性大鼠的口服致死剂量大于 5000mg/kg,且雄性和雌性大鼠的提取物无观察到不良效应水平(NOAEL)被认为是 200mg/kg/天。